Medtronic presses on with DIAM trials
This article was originally published in Clinica
Medtronic is embarking on a European study to demonstrate the benefits of its DIAM spinal stabilisation system in reducing lower back pain in standard herniectomy procedures. The trial is expected to end in 2009, with clinical endpoints of back pain relief at six months and reduction of disability at 12 months. DIAM is already CE-marked for sale in Europe, where the latest study is being performed to validate the indication, as it relates to reimbursement. Two further trials are scheduled for completion in 2009 and 2010, respectively. The product will become available in the US "at clinical trial completion" said the firm. Medtronic claims that DIAM is the only non-rigid interspinous spacer under clinical investigation.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.